BrightSpring Health Services, Inc.
For the period ended Jun 30, 2025. Filed Aug 1, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 1, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders' Equity
(In thousands, except share data)
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Loss · NoncontrollingInterest · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balances at March 31, 2025 | 175,183,434 | $1,752 | $1,880,099 | $(192,613) | $(1,869) | $(125) | $1,687,244 |
| Net income (loss) (1) | — | — | — | 28,208 | — | (158) | 28,050 |
| Other comprehensive loss, net of tax | — | — | — | — | (2,461) | — | (2,461) |
| Share-based compensation | — | — | 22,802 | — | — | — | 22,802 |
| Exercise of stock options | 1,283,882 | 14 | 8,703 | — | — | — | 8,717 |
| Issuance of common stock for settlement of RSUs | 649,010 | 6 | (6) | — | — | — | — |
| Tax effect of net share settlement of equity awards | (60,999) | (1) | (1,744) | — | — | — | (1,745) |
| Balances at June 30, 2025 | 177,055,327 | $1,771 | $1,909,854 | $(164,405) | $(4,330) | $(283) | $1,742,607 |
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · NoncontrollingInterest · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balances at March 31, 2024 | 171,190,389 | $1,712 | $1,788,728 | $(246,069) | $23,115 | $518 | $1,568,004 |
| Net income (loss) (1) | — | — | — | 19,919 | — | (139) | 19,780 |
| Other comprehensive loss, net of tax | — | — | — | — | (4,090) | — | (4,090) |
| Share-based compensation | — | — | 15,136 | — | — | — | 15,136 |
| Shares issued under share-based compensation plan, including tax effects | 107,389 | 1 | 21 | — | — | — | 22 |
| Shares issued for payment of acquisition | 99,252 | 1 | 1,080 | — | — | — | 1,081 |
| Balances at June 30, 2024 | 171,397,030 | $1,714 | $1,804,965 | $(226,150) | $19,025 | $379 | $1,599,933 |
(1) Net loss to the Company for the three months ended June 30, 2025 and 2024 excludes$(508) and$(339), respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.
Condensed Consolidated Statements of Shareholders’ Equity (continued)
(In thousands, except share data)
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · NoncontrollingInterest · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balances at December 31, 2024 | 174,245,990 | $1,742 | $1,866,850 | $(222,155) | $1,418 | $— | $1,647,855 |
| Net income (loss) (1) | — | — | — | 57,750 | — | (283) | 57,467 |
| Other comprehensive loss, net of tax | — | — | — | — | (5,748) | — | (5,748) |
| Share-based compensation | — | — | 38,483 | — | — | — | 38,483 |
| Exercise of stock options | 1,320,135 | 14 | 9,048 | — | — | — | 9,062 |
| Issuance of common stock for settlement of RSUs | 1,701,546 | 17 | (17) | — | — | — | — |
| Tax effect of net share settlement of equity awards | (212,344) | (2) | (4,510) | — | — | — | (4,512) |
| Balances at June 30, 2025 | 177,055,327 | $1,771 | $1,909,854 | $(164,405) | $(4,330) | $(283) | $1,742,607 |
| Common Stock · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · NoncontrollingInterest · Total | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balances at December 31, 2023 | 117,857,055 | $1,179 | $771,336 | $(200,319) | $12,544 | $670 | $585,410 |
| Net loss (1) | — | — | — | (25,831) | — | (291) | (26,122) |
| Other comprehensive income, net of tax | — | — | — | — | 6,481 | — | 6,481 |
| Share-based compensation | — | — | 39,984 | — | — | — | 39,984 |
| Shares issued under share-based compensation plan, including tax effects | 107,389 | 1 | 21 | — | — | — | 22 |
| Shares issued for payment of acquisition | 99,252 | 1 | 1,080 | — | — | — | 1,081 |
| Derecognition of redeemable noncontrolling interest | — | — | 14,981 | — | — | — | 14,981 |
| Issuance of common stock on initial public offering, net (2) | 53,333,334 | 533 | 655,952 | — | — | — | 656,485 |
| Proceeds from stock purchase contract issued under tangible equity units, net (3) | — | — | 321,611 | — | — | — | 321,611 |
| Balances at June 30, 2024 | 171,397,030 | $1,714 | $1,804,965 | $(226,150) | $19,025 | $379 | $1,599,933 |
(1) Net loss to the Company for the six months ended June 30, 2025 and 2024 excludes$(915) and$(822), respectively, allocable to the redeemable noncontrolling interests for our joint venture arrangements.
(2)Issuance of common stock on initial public offering is presented net of underwriting discounts and commissions, and offering-related expenses of $36.8 million.
(3) Proceeds from stock purchase contract issued under tangible equity units is presented net of underwriting discounts and commissions of $9.1 million.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.